title: [A Case of Resection of Para-Aortic Lymph Node Recurrence Three Years after Curative Surgery for Ascending Colon Cancer].
abstract: A79 -year-old woman underwent right hemicolectomy and D3 dissection for ascending colon cancer. Pathologically, the tumor was diagnosed as moderately differentiated adenocarcinoma, pSS, ly1, v1, pPM0, pDM0, pRM0, pN1(3/19), M0, pStage III a. Adjuvant chemotherapy using UFT/UZEL was administered. One and a half years after surgery, PET-CT showed para-aortic lymph node swelling with high FDG uptake. Chemotherapy administration(capecitabine plus bevacizumab)was started and the lymph node swelling reduced. However, 1 year after chemotherapy, the node was swollen again. Para-aortic lymphadenectomy was performed. Pathological examination of the resected specimen showed metastatic adenocarcinoma. No adjuvant chemotherapy was administered. Three years after the last surgery, the patient is alive without any sign of recurrence. In this case, surgical treatment for para-aortic lymph node metastasis of colon cancer resulted in excellent QOL maintenance. We recommend para-aortic lymphadenectomy if the metastasis is localized.
authors.affiliation: Dept. of Gastroenterological Surgery, Graduate School of Medicine, Osaka University.
authors.forename: Yujiro
authors.initials: Y
authors.lastname: Nishizawa
authors.forename: Taishi
authors.initials: T
authors.lastname: Hata
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Takahashi
authors.forename: Naotsugu
authors.initials: N
authors.lastname: Haraguchi
authors.forename: Junichi
authors.initials: J
authors.lastname: Nishimura
authors.forename: Chu
authors.initials: C
authors.lastname: Matsuda
authors.forename: Tsunekazu
authors.initials: T
authors.lastname: Mizushima
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Yamamoto
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Doki
authors.forename: Masaki
authors.initials: M
authors.lastname: Mori
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001011:Aorta / Q000473:pathology / Q000601:surgery; D000068258:Bevacizumab / Q000008:administration & dosage; D000069287:Capecitabine / Q000008:administration & dosage; D044682:Colon, Ascending / Q000473:pathology* / Q000601:surgery; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000473:pathology* / Q000601:surgery; D008207:Lymphatic Metastasis; D012008:Recurrence; D013997:Time Factors
chemical_list: D000068258:Bevacizumab; D000069287:Capecitabine